Release Date: August 15, 2025
Expiration Date: August 15, 2026
Activity Overview
TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells while reducing off-target effects. In this activity, two experts in TNBC management discuss the rationales for using ADCs and the benefits of targeting TROP2 in this disease state.
Target Audience
This activity is directed toward medical oncologists, advanced practice providers, nurses, pharmacists, and other health care providers who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the mechanistic rationale for utilizing ADCs to target TROP2 in the management of patients with metastatic TNBC
- Evaluate recent evidence supporting the evolving role of ADCs in the management of patients with metastatic TNBC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here